Biogen (BIIB) Non-Current Deferred Tax Liability (2009 - 2026)

Biogen has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $945.5 million in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 699.24% year-over-year to $945.5 million in Q2 2026; TTM through Jun 2026 was $945.5 million, a 699.24% increase from a year earlier, with the FY2025 full-year figure at $507.6 million, up 166.46% from the prior year.
• Non-Current Deferred Tax Liability was $945.5 million for Q2 2026 at Biogen, up from $483.5 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $945.5 million in Q2 2026, with the low at $118.3 million in Q2 2025.
• Average Non-Current Deferred Tax Liability over 5 years is $463.8 million, with a median of $482.0 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability tumbled 79.97% in 2025, then jumped 699.24% in 2026.
• Over 5 years, Non-Current Deferred Tax Liability stood at $334.7 million in 2022, then jumped by 91.75% to $641.8 million in 2023, then plunged by 70.32% to $190.5 million in 2024, then soared by 166.46% to $507.6 million in 2025, then surged by 86.27% to $945.5 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $945.5 million (Q2 2026), $483.5 million (Q1 2026), and $507.6 million (Q4 2025), per Business Quant data.